Drugs / Plonmarlimab
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04457856 | Aug 2020 → Mar 2023 | rheumatoid arthritis | I-Mab Biopharma US Limited | Unknown | No outcome recorded |
| Phase 1 | NCT03794180 | Mar → Sep 2019 | — | I-Mab Biopharma US Limited | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07453004 | Mar 2026 → Dec 2027 expected | gout | TJ Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07034209 | Apr 2023 → Apr 2025 | hemophagocytic syndrome | TJ Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04341116 | Apr 2020 → Feb 2022 | COVID-19 | I-Mab Biopharma US Limited | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07208058 | Nov 2025 → Dec 2026 expected | secondary hemophagocytic lymphohistiocytosis | TJ Biopharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plonmarlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07034209 ↗ |
| Known as | TJ003234 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04457856 ↗ |
| Known as | TJM-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650518 ↗ |
| Action | Inhibit | “Anti-Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) Monoclonal Antibody” NCT03794180 ↗1“Granulocyte-macrophage colony-stimulating factor antagonist” CHEMBL4650518 ↗ |
| Modality | Monoclonal antibody | “Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline” NCT03794180 ↗ |
| Route | Intravenous | “administered as an intravenous (IV) infusion” NCT03794180 ↗ |
| Target | CSF2 | “Granulocyte-macrophage colony-stimulating factor antagonist” CHEMBL4650518 ↗ |